Press Releases
-
Oz-UK Ltd announces new low-GWP manufacturing line installation to meet global need for pMDIs ahead of the Kigali Amendment deadline
Oz-UK Ltd announces the installation of its new low-GWP (global warming potential) manufacturing line.
Dec 14, 2023
-
Analyzing Delivery Systems: CD Formulation Introduces In Vitro Testing to Measure Microsphere and Microneedle Release
-
ReciBioPharm partners with Acuitas Therapeutics to provide rapid technology transfers and CGMP manufacture of Acuitas’ LNP formulations
I just wanted to follow up to see if you had received my initial email regarding ReciBioPharm partners with Acuitas Therapeutics? Please let me know if there is any further information you require from me for this.
Dec 14, 2023
-
TransCure bioServices strengthens team with C-suite hire and boosts North American preclinical opportunities
TransCure bioServices has announced the appointment of Céline Pinault as its new Chief Financial Officer.
Dec 12, 2023
-
Joint report from Ashfield Event Experiences, part of Inizio Engage XD, and IPCAA provides insights to drive future medical congress and convention success
I wanted to share some exciting insights from a joint report by Ashfield Event Experiences, part of Inizio Engage XD, and the International Pharmaceutical Congress Advisory Association (IPCAA). This report delves into the evolving landscape of healthcare provider (HCP) behaviors and attitudes towards medical congresses and conventions, particularly in the context of the return of in-person events. The full release is below.
Dec 12, 2023
-
VLPlant™ Is Set to Revolutionize Viral Vaccine Development
-
Ace Neuroscience Launches Drug Development Services for Stroke and Psychiatric Disorders
-
Amerigo Scientific's New Lab Offering: S-Silver SERS Substrates
-
Abzena Partners with ProteoNic to Offer Enhanced CHO Cell Line Platform for Complex Biologics
-
Lightship & Acclinate Introduce Season of Giving — Initiative to Support Communities That Give Time for Clinical Research
As part of this Season of Giving initiative, Lightship and Acclinate are extending an open call for other clinical research industry and health-focused organizations to join them for future events.
Dec 3, 2023
-
Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) Announce Collaboration for Low GWP Propellant Conversion
Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) Fluorinated Solutions business (Koura®), a global leader in the development, manufacture, and supply of fluoroproducts and technologies, announced today a co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Koura’s more sustainable and environmentally-conscious medical propellant; HFA 152a, known as Zephex® 152a.
Dec 4, 2023
-
X-Chem Announces Achievement of Collaboration Milestone
X-Chem, a global leader in innovative drug discovery services, announces the achievement of a drug discovery milestone, following a partner’s attainment of a development candidate. Relay Therapeutics, a leader in cutting-edge approaches to drug discovery, utilized X-Chem’s DNA-Encoded Library (DEL) platform to perform hit finding intended to discover molecules with differentiated pharmacological properties. The resulting molecule led to a development candidate — a milestone under the companies’ collaboration agreement and to progress in evaluation.
Dec 4, 2023
-
Recipharm announces collaboration with Oz-UK to accelerate the development of low global warming potential pMDIs utilising HFA-152a propellant
Please see below news from Recipharm on its collaboration with CRO, Oz-UK to accelerate the development of low global warming pressurised Metered Dose Inhalers (pMDIs). It has also announced the appointment of Simon Gardner, formerly of HFA-152a propellant supplier, Koura to support customers in their transition to greener propellants.
Dec 4, 2023
-
Julius Clinical Research Receives Growth Investment from Ampersand Capital Partners
Julius Clinical Research Receives Growth Investment from Ampersand Capital Partners. Partnership will further expand Julius’ clinical trial services capabilities to advance new therapeutics.
Dec 3, 2023
-
Biotium launches new line of extensively validated primary antibody conjugates for flow cytometry
Biotium has announced the launch of Biotium Choice primary antibody conjugates. With careful curation and extensive in-house validation, Biotium Choice monoclonal primary antibodies are designed to deliver exceptional performance for flow cytometry.
Dec 3, 2023
-
WCG Revolutionizes Ethical Review Process with IRB+ Service, Achieving Unprecedented Efficiency Gains
WCG's IRB+ service has been pressure tested on 90+ studies, ensuring that it maintains the integrity and quality of board reviews while accelerating operational processing, allowing for faster site activation and study start-up.
Nov 29, 2023
-
Ardena's new Aseptic Fill-Finish Plant in Ghent receives GMP license
-
CD Genomics Unveils Cutting-Edge 5mC/5hmC Sequencing Service to Drive Epigenomics Research Forward
-
CD Genomics Takes Genomic Research to New Heights with Ribo-seq Technology
-
Sygnature Discovery appoints new industry leaders to their board of directors
I'm getting in touch with the latest news from Sygnature Discovery, a world-leading contract research organization. The company has recently appointed two industry leaders, Vanessa Malier and Martin LeBlanc, to their board of directors, reinforcing its commitment to innovation and strategic leadership. With decades of experience and a wealth of expertise in their respective fields, both Martin and Vanessa bring unique and valuable perspectives to Sygnature Discovery's board.
Nov 29, 2023